Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
InflaRx N.V.
IFRX
$1.47
Name : InflaRx N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $99,588,280.00
EPSttm : -0.85
finviz dynamic chart for IFRX
InflaRx N.V.
$1.47
6.52%
$0.09

Float Short %

1.21

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.1

EPS Last/This Y

0.31

EPS This/Next Y

0.08

Price

1.37

Target Price

4.16

Analyst Recom

1.38

Performance Q

54.35

Relative Volume

1.59

Beta

1.39

Ticker: IFRX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-09-08IFRX1.590.000.009349
2025-09-09IFRX1.5250.000.009876
2025-09-10IFRX1.580.000.0010666
2025-09-11IFRX1.4650.000.0010963
2025-09-12IFRX1.250.000.0010962
2025-09-15IFRX1.2150.000.0010973
2025-09-16IFRX1.1350.000.0011003
2025-09-17IFRX1.180.0010898192716375011023
2025-09-18IFRX1.380.000.0211257
2025-09-22IFRX1.3550.000.0010521
2025-09-23IFRX1.30.000.0010634
2025-09-24IFRX1.380.000.0010654
2025-09-25IFRX1.280.000.0010650
2025-09-26IFRX1.3050.000.0011092
2025-09-29IFRX1.350.000.0011326
2025-09-30IFRX1.3350.000.0011248
2025-10-01IFRX1.340.000.0011484
2025-10-02IFRX1.380.000.0011700
2025-10-03IFRX1.620.000.0011851
2025-10-06IFRX1.50.000.0011911
2025-10-07IFRX1.3720.000.0011912
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-09-08IFRX1.5859.2-11.2-0.60
2025-09-09IFRX1.5259.2-12.4-0.60
2025-09-10IFRX1.5959.2-23.8-0.60
2025-09-11IFRX1.4759.2-8.2-0.60
2025-09-12IFRX1.2559.23.5-0.60
2025-09-15IFRX1.2059.2-8.8-0.60
2025-09-16IFRX1.1459.2-3.1-0.60
2025-09-17IFRX1.1759.2-27.3-0.60
2025-09-18IFRX1.3859.2-57.6-0.60
2025-09-19IFRX1.3259.2-11.9-0.60
2025-09-22IFRX1.3559.2-19.5-0.60
2025-09-23IFRX1.2959.2-10.4-0.60
2025-09-24IFRX1.3859.2-31.8-0.60
2025-09-25IFRX1.2959.2-10.5-0.60
2025-09-26IFRX1.3059.2-20.2-0.60
2025-09-29IFRX1.3659.2-27.2-0.60
2025-09-30IFRX1.3459.2-13.0-0.60
2025-10-01IFRX1.3559.2-21.9-0.60
2025-10-02IFRX1.3859.2-21.0-0.60
2025-10-03IFRX1.6259.2-48.5-0.60
2025-10-06IFRX1.5259.2-35.8-0.60
2025-10-07IFRX1.3759.2-3.7-0.60
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-09-08IFRX0.00-6.441.45
2025-09-09IFRX0.00-6.441.45
2025-09-10IFRX0.00-6.441.45
2025-09-11IFRX0.00-6.440.72
2025-09-12IFRX0.00-6.440.72
2025-09-15IFRX0.00-6.440.72
2025-09-16IFRX0.00-6.440.72
2025-09-17IFRX0.00-6.440.72
2025-09-18IFRX0.00-6.440.72
2025-09-19IFRX0.00-6.440.72
2025-09-22IFRX0.00-6.440.72
2025-09-23IFRX0.00-6.440.72
2025-09-24IFRX0.00-6.440.72
2025-09-25IFRX0.00-6.441.21
2025-09-26IFRX0.00-6.441.21
2025-09-29IFRX0.00-6.441.21
2025-09-30IFRX0.00-6.441.21
2025-10-01IFRX0.00-6.441.21
2025-10-02IFRX0.00-6.441.21
2025-10-03IFRX0.00-6.441.21
2025-10-06IFRX0.00-1.461.21
2025-10-07IFRX0.00-1.461.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.24

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

-1.46

Beta

1.39

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

22

Growth Score

25

Sentiment Score

88

Actual DrawDown %

81.1

Max Drawdown 5-Year %

-88.5

Target Price

4.16

P/E

Forward P/E

PEG

P/S

514.68

P/B

1.4

P/Free Cash Flow

EPS

-1.05

Average EPS Est. Cur. Y​

-0.6

EPS Next Y. (Est.)

-0.52

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-33446.72

Relative Volume

1.59

Return on Equity vs Sector %

-104.6

Return on Equity vs Industry %

-90.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

-3.7
InflaRx N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 74
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
stock quote shares IFRX – InflaRx N.V. Stock Price stock today
news today IFRX – InflaRx N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch IFRX – InflaRx N.V. yahoo finance google finance
stock history IFRX – InflaRx N.V. invest stock market
stock prices IFRX premarket after hours
ticker IFRX fair value insiders trading